Published in Am J Hematol on April 01, 2007
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood (2009) 1.83
Detrimental effects of adenosine signaling in sickle cell disease. Nat Med (2010) 1.54
Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease. Am J Hematol (2009) 1.48
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol (2011) 1.45
Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion (2013) 1.43
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol (2010) 1.28
Liver iron content determination by magnetic resonance imaging. World J Gastroenterol (2010) 1.21
Iron overload in sickle cell disease. Adv Hematol (2010) 1.15
Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med (2008) 1.07
Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease. Osteoporos Int (2016) 0.99
Iron metabolism in thalassemia and sickle cell disease. Mediterr J Hematol Infect Dis (2009) 0.95
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion (2008) 0.94
Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med (2011) 0.90
Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications. Mediterr J Hematol Infect Dis (2009) 0.88
Secondary haemochromatosis in a patient with thalassemia intermedia. Curr Health Sci J (2013) 0.86
Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone (2008) 0.85
Iron overload in Beta thalassaemia major and intermedia patients. Maedica (Buchar) (2013) 0.85
Impact of iron overload on interleukin-10 levels, biochemical parameters and oxidative stress in patients with sickle cell anemia. Rev Bras Hematol Hemoter (2013) 0.84
Hepatic Iron Quantification on 3 Tesla (3 T) Magnetic Resonance (MR): Technical Challenges and Solutions. Radiol Res Pract (2013) 0.84
Inadequate dietary intake in patients with thalassemia. J Acad Nutr Diet (2012) 0.79
Trends in blood transfusion among hospitalized children with sickle cell disease. Pediatr Blood Cancer (2013) 0.78
Erythropoietic drive is the strongest predictor of hepcidin level in adults with sickle cell disease. Blood Cells Mol Dis (2015) 0.77
A comparison between whites and blacks with severe multi-organ iron overload identified in 16,152 autopsies. Clin Gastroenterol Hepatol (2009) 0.76
Severe cardiac iron toxicity in two adults with sickle cell disease. Transfusion (2016) 0.75
Acquired hemochromatosis with pronounced pigment deposition of the upper eyelids. J Clin Aesthet Dermatol (2013) 0.75
Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfus (2012) 0.75
β-Thalassemia and ocular implications: a systematic review. BMC Ophthalmol (2016) 0.75
Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome. PLoS One (2017) 0.75
How we manage iron overload in sickle cell patients. Br J Haematol (2017) 0.75
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA (2003) 8.18
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Pulmonary complications of sickle cell disease. N Engl J Med (2008) 4.11
A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med (2006) 4.04
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol (2010) 3.78
Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med (2003) 2.93
Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics (2008) 2.61
Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol (2010) 2.55
High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood (2013) 2.41
Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney Int (2004) 2.16
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA (2006) 2.04
Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr (2003) 2.00
Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol (2006) 1.99
Early elevation of plasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation. Pediatr Crit Care Med (2007) 1.92
Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med (2011) 1.89
Mucopolysaccharidosis VI. Orphanet J Rare Dis (2010) 1.87
Thalassemia. Hematology Am Soc Hematol Educ Program (2004) 1.83
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood (2009) 1.83
Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol (2002) 1.73
Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood (2004) 1.66
Management guidelines for mucopolysaccharidosis VI. Pediatrics (2007) 1.61
Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res (2009) 1.61
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis (2014) 1.60
Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A (2005) 1.58
Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol (2006) 1.57
Balloon dilation for achalasia of the cardia: experience in 76 patients. Radiology (2002) 1.54
Blood product transfusions and clinical outcomes in pediatric patients with acute lung injury. Pediatr Crit Care Med (2009) 1.53
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood (2002) 1.52
Silent infarcts in young children with sickle cell disease. Br J Haematol (2009) 1.51
Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr (2002) 1.50
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol (2013) 1.49
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease. Am J Hematol (2009) 1.48
Preventive health care measures before and after start of renal replacement therapy. J Gen Intern Med (2002) 1.47
The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Med (2011) 1.45
Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am (2006) 1.44
Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol (2005) 1.41
The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood (2010) 1.41
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
I beg to differ. CMAJ (2002) 1.38
Summary of symposium: the future of stem cell transplantation for sickle cell disease. J Pediatr Hematol Oncol (2002) 1.37
Utilization of the office, hospital and emergency department for adult sickle cell patients: a five-year study. J Natl Med Assoc (2006) 1.35
Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium. Pediatr Blood Cancer (2010) 1.33
Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat (2007) 1.30
The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur J Pediatr (2011) 1.27
Assessment of sickle cell pain in children and young adults using the adolescent pediatric pain tool. J Pain Symptom Manage (2002) 1.27
Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr (2009) 1.27
Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica (2008) 1.26
Extranodal Rosai-Dorfman disease in children. J Pediatr Hematol Oncol (2004) 1.23
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23
Gene interactions and stroke risk in children with sickle cell anemia. Blood (2003) 1.23
Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). J Pediatr Hematol Oncol (2002) 1.22
Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease. Am J Cardiol (2009) 1.22
Sickle cell hepatopathy: clinical presentation, treatment, and outcome in pediatric and adult patients. Pediatr Blood Cancer (2005) 1.21
Non-transfusion-dependent thalassemias. Haematologica (2013) 1.21
The third described case of transfusion-transmitted Babesia duncani. Transfusion (2011) 1.21
Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease. J Pediatr (2010) 1.21
International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet A (2014) 1.19
Parent factors and adolescent sickle cell disease: associations with patterns of health service use. J Pediatr Psychol (2002) 1.19
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica (2008) 1.18
Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood (2007) 1.17
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood (2010) 1.17
Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer (2007) 1.17
Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood (2009) 1.16
Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias". J Am Soc Nephrol (2005) 1.16
Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol (2009) 1.15
The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level. Free Radic Biol Med (2008) 1.15
Cognitive impairment in children with hemoglobin SS sickle cell disease: relationship to MR imaging findings and hematocrit. AJNR Am J Neuroradiol (2003) 1.15
Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer (2009) 1.15
Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol (2011) 1.15
Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis (2013) 1.14
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann N Y Acad Sci (2005) 1.14
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PLoS One (2013) 1.14
Placenta growth factor in sickle cell disease: association with hemolysis and inflammation. Blood (2009) 1.13
Newborn screening program for hemoglobinopathies in Rio de Janeiro, Brazil. Pediatr Blood Cancer (2013) 1.13
Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol (2007) 1.13
The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS). Mol Genet Metab (2013) 1.12
Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med (2010) 1.11
Is treatment adherence associated with better quality of life in children with sickle cell disease? Qual Life Res (2005) 1.11
Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol (2011) 1.10
Bone density assessment in patients with mucopolysaccharidosis: A preliminary report from patients with MPS II and VI. J Pediatr Rehabil Med (2010) 1.09
A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am J Hematol (2012) 1.09